ProfileGDS5678 / 1458941_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 41% 47% 48% 47% 48% 43% 43% 65% 46% 46% 45% 45% 45% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9804241
GSM967853U87-EV human glioblastoma xenograft - Control 23.0939447
GSM967854U87-EV human glioblastoma xenograft - Control 33.1250848
GSM967855U87-EV human glioblastoma xenograft - Control 43.0470947
GSM967856U87-EV human glioblastoma xenograft - Control 53.0780148
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0950643
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0637643
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9093465
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0549546
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0643346
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0443645
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.0252645
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0695945
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0299944